id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2017-E-5054-0007,FDA,FDA-2017-E-5054,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2019-09-17T04:00:00Z,2019,9,2019-09-17T04:00:00Z,,2019-09-17T14:05:08Z,,0,0,0900006483f87666
FDA-2017-E-5054-0006,FDA,FDA-2017-E-5054,"Determination of Regulatory Review Period for Purposes of Patent
Extension; EXONDYS 51",Notice,Determinations,2019-02-11T05:00:00Z,2019,2,2019-02-11T05:00:00Z,2019-04-13T03:59:59Z,2019-02-11T12:43:31Z,2019-01851,0,0,0900006483a5e664
FDA-2017-E-5054-0005,FDA,FDA-2017-E-5054,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2018-12-21T05:00:00Z,2018,12,2018-12-21T05:00:00Z,,2018-12-21T18:14:25Z,,0,0,09000064839c07ab
FDA-2017-E-5054-0004,FDA,FDA-2017-E-5054,Letter from U.S. Patent and Trademark Office to  FDA CDER,Other,Letter(s),2018-10-02T04:00:00Z,2018,10,2018-10-02T04:00:00Z,,2018-10-02T16:12:22Z,,0,0,090000648378c7ea
FDA-2017-E-5054-0003,FDA,FDA-2017-E-5054,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2017-10-17T04:00:00Z,2017,10,2017-10-17T04:00:00Z,,2017-10-17T21:08:29Z,,0,0,0900006482bd5ab9
FDA-2017-E-5054-0002,FDA,FDA-2017-E-5054,Letter from U.S. Patent and Trademark Office,Other,Letter(s),2017-08-18T04:00:00Z,2017,8,2017-08-18T04:00:00Z,,2017-08-18T15:11:39Z,,0,0,0900006482a61736
FDA-2017-E-5054-0001,FDA,FDA-2017-E-5054,Patent Extension Application from Nelson Mullins Riley & Scarborough LLP (on behalf of The University of Western Australia),Other,Letter(s),2017-08-18T04:00:00Z,2017,8,2017-08-18T04:00:00Z,,2017-08-18T15:03:32Z,,0,0,0900006482a61a07